Breye Therapeutics
Breye Therapeutics is a clinical-stage biopharmaceutical company developing orally administered drugs for ophthalmology. The company's pipeline includes danegaptide, a small molecule drug for diabetic retinopathy, and P2X7 receptor antagonists with anti-inflammatory and neuroprotective properties. These therapies aim to provide less burdensome treatment options for patients at risk of vision loss.
Visit websiteHørsholm, Denmark
Biotechnology
Ophthalmology
Pharmaceuticals
Healthcare
Funding summary
- Total raised
- €4.0M
- Funding rounds
- 1
Investors in Breye Therapeutics
Investors on record for Breye Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Breye Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors